Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals Inc (NQ: PIRS )

16.77 UNCHANGED
Streaming Delayed Price Updated: 3:53 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Pieris Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q4, Pieris Pharmaceuticals (NASDAQ:PIRS) posted sales of $8.44 million. Earnings were up 42.36%, but Pieris Pharmaceuticals still reported... 
Via Benzinga
Recap: Pieris Pharmaceuticals Q4 Earnings
Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST - Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year - Dosed first... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Thinking About Buying Stock In Pieris Pharmaceuticals, Baidu Or Cronos Group?
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b... 
Via Benzinga
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The company's market cap stands at $224.5 million. Artelo... 
Via Benzinga
Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT - Dosing completed in part 1a of phase 2a study of PRS-060/AZD1402 - Dosing to begin this quarter in phase 2... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Preview: Pieris Pharmaceuticals's Earnings
Pieris Pharmaceuticals (NASDAQ:PIRS) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement.... 
Via Benzinga
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
3 Biotech Stocks to Watch Now
Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so. Most biotech stocks trade at low prices and... 
Via Benzinga
Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market session. The company's market cap stands at $24.5... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Stealth BioTherapeutics (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Impel NeuroPharma (NASDAQ:IMPL) shares increased by 22.16% to $20.29 during Thursday's regular session. Trading volume for this security as of 12:30 EST is 1.1... 
Via Benzinga
35 Stocks Moving In Thursday's Mid-Day Session
Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE:... 
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
48 Biggest Movers From Yesterday
Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy... 
Via Benzinga
Which Biotech Stock Will Shock the Market in 2022?
Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022? 
Via The Motley Fool
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Exposures COVID-19 Product Safety
Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
BOSTON, MA / ACCESSWIRE / August 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDT - Announced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.